• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床实践中的降脂营养保健品:国际脂质专家小组的立场文件。

Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

机构信息

Department of Medicine and Surgery Sciences, University of Bologna, Bologna, Italy; and Italian Society of Nutraceuticals.

Clinic of Cardiology, University Clinical Centre of Kosovo, Prishtina, Kosovo; Medical Faculty, University of Prishtina, Prishtina, Kosovo; and Kosovo Society of Cardiology.

出版信息

Nutr Rev. 2017 Sep 1;75(9):731-767. doi: 10.1093/nutrit/nux047.

DOI:10.1093/nutrit/nux047
PMID:28938795
Abstract

In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.

摘要

近年来,人们对营养保健品在改善和优化血脂异常控制和治疗方面的潜在应用越来越感兴趣。基于现有研究的数据,营养保健品可能有助于患者实现治疗性的血脂目标,并降低心血管残余风险。一些营养保健品具有在研究中得到证实的基本降脂特性;一些营养保健品也可能对非脂心血管危险因素有积极影响,并已被证明可改善血管健康的早期标志物,如内皮功能和脉搏波速度。然而,支持使用单一降脂营养保健品或其组合的临床证据在很大程度上是可变的,而且对于许多营养保健品,证据非常有限,因此往往存在争议。本立场文件的目的是提供基于共识的建议,以优化降脂营养保健品的使用,管理尚未接受他汀类药物治疗的患者、已接受他汀类药物或联合治疗但未达到血脂目标的患者以及他汀类药物不耐受的患者的血脂异常。本声明适用于参与诊断和管理血脂异常患者的医生和其他医疗保健专业人员,特别是在初级保健环境中。

相似文献

1
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.临床实践中的降脂营养保健品:国际脂质专家小组的立场文件。
Nutr Rev. 2017 Sep 1;75(9):731-767. doi: 10.1093/nutrit/nux047.
2
The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia.营养保健品在血脂异常高危患者降脂治疗中的作用。
Curr Atheroscler Rep. 2020 Sep 18;22(11):67. doi: 10.1007/s11883-020-00887-z.
3
Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.在欧洲和加拿大的临床实践中,他汀类药物治疗患者的持续性脂质异常及 LDL-胆固醇目标达标率的预测因子。
Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.
4
Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.美国接受他汀类药物治疗成年人中根据低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和载脂蛋白B划分的残余血脂异常:2009 - 2010年美国国家健康和营养检查调查
J Clin Lipidol. 2015 Jul-Aug;9(4):525-32. doi: 10.1016/j.jacl.2015.05.003. Epub 2015 May 16.
5
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.在管理式医疗环境中,以低高密度脂蛋白胆固醇为靶点降低残余心血管风险。
J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1.
6
Persistent dyslipidemia in statin-treated patients: the focus on comprehensive lipid management survey in Swiss patients.瑞仕安患者血脂异常管理调查:关注他汀治疗患者血脂管理的多方面问题
Swiss Med Wkly. 2011 May 13;141:w13200. doi: 10.4414/smw.2011.13200. eCollection 2011.
7
Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.高心血管风险患者血脂水平达标情况:来自英国、瑞典、西班牙和加拿大的观察性研究的汇总分析。
Eur J Intern Med. 2013 Oct;24(7):656-63. doi: 10.1016/j.ejim.2013.07.005. Epub 2013 Aug 13.
8
Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.法国全科医疗中接受降脂治疗患者的混合性血脂异常:一项观察性研究。
Clin Ther. 2007 Aug;29(8):1671-81. doi: 10.1016/j.clinthera.2007.08.003.
9
The Role of Nutraceuticals in Statin Intolerant Patients.营养药物在他汀不耐受患者中的作用。
J Am Coll Cardiol. 2018 Jul 3;72(1):96-118. doi: 10.1016/j.jacc.2018.04.040.
10
Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).中国接受降脂药物治疗患者的血脂异常患病率:血脂异常国际研究(DYSIS)结果
Atherosclerosis. 2014 Aug;235(2):463-9. doi: 10.1016/j.atherosclerosis.2014.05.916. Epub 2014 Jun 5.

引用本文的文献

1
Lupeol Attenuates Oxysterol-Induced Dendritic Cell Activation Through NRF2-Mediated Antioxidant and Anti-Inflammatory Effects.羽扇豆醇通过NRF2介导的抗氧化和抗炎作用减轻氧化甾醇诱导的树突状细胞活化。
Int J Mol Sci. 2025 Jul 25;26(15):7179. doi: 10.3390/ijms26157179.
2
A natural small molecule isoginkgetin alleviates hypercholesterolemia and atherosclerosis by targeting ACLY.一种天然小分子异银杏双黄酮通过靶向ACLY减轻高胆固醇血症和动脉粥样硬化。
Theranostics. 2025 Mar 18;15(10):4325-4344. doi: 10.7150/thno.105782. eCollection 2025.
3
Global hotspots and trends of nutritional supplements for sick populations from 2000 to 2024.
2000年至2024年患病群体营养补充剂的全球热点与趋势
Front Nutr. 2025 Jan 28;12:1497207. doi: 10.3389/fnut.2025.1497207. eCollection 2025.
4
L. Seed Oil Modulates Dyslipidemia and Neuronal Dysfunction in Tramadol-Induced Toxicity in Wistar Albino Rats.月见草籽油调节曲马多诱导的Wistar白化大鼠毒性中的血脂异常和神经元功能障碍。
Dose Response. 2024 Oct 6;22(4):15593258241290458. doi: 10.1177/15593258241290458. eCollection 2024 Oct-Dec.
5
Chinese expert consensus on blood lipid management in patients with diabetes (2024 edition).《中国糖尿病患者血脂管理专家共识(2024年版)》
J Transl Int Med. 2024 Oct 1;12(4):325-343. doi: 10.2478/jtim-2024-0014. eCollection 2024 Sep.
6
Evaluating the Efficacy of Resveratrol-Containing Mouthwash as an Adjunct Treatment for Periodontitis: A Randomized Clinical Trial.评估含白藜芦醇漱口水作为牙周炎辅助治疗方法的疗效:一项随机临床试验。
Eur J Dent. 2025 May;19(2):354-365. doi: 10.1055/s-0044-1788686. Epub 2024 Sep 9.
7
Effects of the combination of red yeast rice-containing commercial Chinese polyherbal preparation with statins for dyslipidemia: a systematic review and meta-analysis.含红曲米的市售中药复方制剂与他汀类药物联合治疗血脂异常的效果:一项系统评价和荟萃分析。
Front Pharmacol. 2024 Jul 23;15:1398934. doi: 10.3389/fphar.2024.1398934. eCollection 2024.
8
Traditional Chinese medicine lowering lipid levels and cardiovascular events across baseline lipid levels among coronary heart disease: a meta-analysis of randomized controlled trials.冠心病患者中,中药降低血脂水平及降低不同基线血脂水平患者心血管事件风险的随机对照试验的荟萃分析
Front Cardiovasc Med. 2024 Jul 11;11:1407536. doi: 10.3389/fcvm.2024.1407536. eCollection 2024.
9
Efficacy of AI-Guided (GenAIS) Dietary Supplement Prescriptions versus Traditional Methods for Lowering LDL Cholesterol: A Randomized Parallel-Group Pilot Study.人工智能指导(GenAIS)膳食补充剂处方与传统方法降低 LDL 胆固醇的疗效比较:一项随机平行组试验研究。
Nutrients. 2024 Jun 26;16(13):2023. doi: 10.3390/nu16132023.
10
Phenolic Compounds from Cherries and Berries for Chronic Disease Management and Cardiovascular Risk Reduction.樱桃和浆果中的酚类化合物可用于慢性疾病管理和降低心血管疾病风险。
Nutrients. 2024 May 23;16(11):1597. doi: 10.3390/nu16111597.